Skip to content
Cancer — AntimetabolitesATC L01BC01

Cytarabine

Prescription onlyWHO essential medicine

Core leukaemia chemotherapy given as infusion or injection.

Starts working
Depends on the cancer and regimen
Half-life
1–3 hours
In use since
—
Pregnancy
Usually avoided

Overview

Cytarabine (cytosine arabinoside) is a key drug for acute myeloid leukaemia and some lymphomas. High doses can affect the cerebellum and eyes, so neurological checks and steroid eye drops are used.

Conditions it's used for

How it works

Blocks leukaemia cells from copying their DNA.

Cytarabine belongs to the Antimetabolites. How Antimetabolites work: look like the raw materials of DNA, so dividing cells make faulty copies or stall.

Uses

  • Acute myeloid leukaemia
  • Acute lymphoblastic leukaemia
  • Lymphoma (including CNS prophylaxis)

Available as: iv infusion, subcutaneous injection, intrathecal injection.

Typical dose

Adults
Dosed by your cancer team according to the treatment protocol.
Good to know
Doses depend on body size, blood counts and the regimen.

Typical doses for orientation only. Your prescription, the pack leaflet and local guidance take priority.

Side effects

Common

Often mild and may settle with time

  • Nausea
  • Fever and flu-like symptoms
  • Rash
  • Low blood counts
  • Mouth sores

Serious — get medical help

Uncommon, but need prompt attention

  • Severe infection from low white cells
  • Cerebellar toxicity (high dose)
  • Conjunctivitis (high dose)

Warnings

  • Steroid eye drops with high doses

Who should avoid it

  • Pregnancy
  • Severe bone marrow suppression unless treating leukaemia

Interactions

  • Digoxin — lower absorption
  • Live vaccines — avoid
  • Flucytosine — reduced effect

Other medicines in the atlas that need care with Cytarabine, grouped by the reason:

Added bone marrow suppressionModerateWith Azathioprine, Bortezomib, Capecitabine, Carbimazole, Carboplatin and 26 more
Bleeding risk with low plateletsModerateWith Aspirin, Cilostazol, Clopidogrel, Dipyridamole, Prasugrel and 1 more

Antiplatelet treatment adds to bleeding risk when another medicine suppresses platelet production.

What's usually done: Monitor blood counts and report unusual bruising or bleeding.

Check Cytarabine against your own medicines

Using it safely

Alcohol
Best to limit. Alcohol can add to nausea and tiredness; ask your cancer team.
Food and drink
Follow your cancer team's advice.
If you miss a dose
Contact your cancer team; do not double up.
Stopping it
Only your cancer team should change or stop treatment.
Driving
Tiredness or dizziness may affect driving.
Tests and checks
Blood counts; Neurological exam in high dose; Liver tests
If too much is taken
Overdose can cause severe low blood counts or organ damage. Seek emergency help.
Storage
Refrigerate unless the label says otherwise.
Legal status
United States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM), hospital useIndia: Schedule HAustralia: Prescription only (Schedule 4)

Pregnancy and breastfeeding

Pregnancy

Usually avoided

Can harm a developing baby. Effective contraception is advised during and after treatment.

Breastfeeding

Usually avoided

Avoid breastfeeding during treatment.

Special groups

Kidney disease
Dose may need adjusting; your team will advise.
Liver disease
Dose may need adjusting; your team will advise.
Older adults
Older adults may be more sensitive to side effects.

Brand names

United States
Cytarabine (generic)
United Kingdom
Cytarabine (generic)
India
Cytarabine (generic), Cytosar
Australia
Cytarabine (generic)

Examples only; many generic versions exist. The same brand name can mean different products in different countries.

Common questions

Do I need a prescription for Cytarabine?

Yes — Cytarabine is prescription-only in most countries.

Can I take Cytarabine during pregnancy?

Usually avoided. Can harm a developing baby. Effective contraception is advised during and after treatment. Always check with a doctor or midwife.

How quickly does Cytarabine work?

Depends on the cancer and regimen.

Sources and official information

Entry last reviewed October 2026. Compiled from WHO, NHS, FDA/DailyMed, BNF and national formulary information. How we write entries.